Lucy Yan

432 total citations
15 papers, 325 citations indexed

About

Lucy Yan is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Lucy Yan has authored 15 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Lucy Yan's work include Acute Myeloid Leukemia Research (3 papers), Migraine and Headache Studies (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Lucy Yan is often cited by papers focused on Acute Myeloid Leukemia Research (3 papers), Migraine and Headache Studies (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Lucy Yan collaborates with scholars based in United States, United Kingdom and Belgium. Lucy Yan's co-authors include Thuy Vu, Gabriel Vargas, Anne Van Hecken, Jan de Hoon, Lisa Hamilton, Brian P. Smith, Teresa L. Burgess, Hongjie Deng, Peiming Ma and Ian M. Leitch and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Lucy Yan

13 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lucy Yan United States	5	130	121	83	74	53	15	325
Hong Qiu United States	12	51 0.4×	44 0.4×	17 0.2×	138 1.9×	19 0.4×	31	342
Ching Hsu United States	10	30 0.2×	24 0.2×	44 0.5×	79 1.1×	130 2.5×	23	356
Torsten Holm Nielsen Denmark	8	52 0.4×	51 0.4×	11 0.1×	71 1.0×	41 0.8×	31	253
Wenting Hou China	11	51 0.4×	11 0.1×	33 0.4×	143 1.9×	31 0.6×	16	353
Yihua Zhao United States	12	61 0.5×	18 0.1×	18 0.2×	124 1.7×	91 1.7×	25	448
Koji Wakatsuki Japan	8	47 0.4×	28 0.2×	20 0.2×	106 1.4×	81 1.5×	14	467
Ilse Kern Switzerland	10	38 0.3×	21 0.2×	17 0.2×	169 2.3×	87 1.6×	19	441
Jen‐Yea Chang United States	9	17 0.1×	16 0.1×	41 0.5×	73 1.0×	49 0.9×	9	331
Iván Cabezas‐Rodríguez Spain	11	7 0.1×	53 0.4×	25 0.3×	62 0.8×	60 1.1×	23	532

Countries citing papers authored by Lucy Yan

Since Specialization

Citations

This map shows the geographic impact of Lucy Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucy Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucy Yan more than expected).

Fields of papers citing papers by Lucy Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucy Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucy Yan. The network helps show where Lucy Yan may publish in the future.

Co-authorship network of co-authors of Lucy Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Lucy Yan. A scholar is included among the top collaborators of Lucy Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucy Yan. Lucy Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Domingue, Benjamin W., Yaacov Petscher, Hugh W. Catts, et al.. (2025). Differences in Reading Screening Accuracy by Percentile Cutoff and English Proficiency: Feature Selection and Group‐Wise Prediction Evaluation. Reading Research Quarterly. 61(1).

Richie-Halford, Adam, et al.. (2025). Design and validation of a rapid visual processing measure for screening reading difficulties in early childhood. Behavior Research Methods. 57(9). 237–237.

Garcia‐Manero, Guillermo, Lewis R. Silverman, Mikkael A. Sekeres, & Lucy Yan. (2024). Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies.. Journal of Clinical Oncology. 42(16_suppl). TPS6591–TPS6591. 1 indexed citations

Garcia‐Manero, Guillermo, Yazan F. Madanat, Mikkael A. Sekeres, et al.. (2024). R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study. Blood. 144(Supplement 1). 4595–4595. 4 indexed citations

Garcia‐Manero, Guillermo, Lucy Yan, & Wolfgang Dummer. (2023). Phase 1b clinical study of IRAK 1/4 inhibition for low-risk myelodysplastic syndromes refractory/resistant to prior therapies.. Journal of Clinical Oncology. 41(16_suppl). TPS7085–TPS7085. 1 indexed citations

Malik, Anuj, et al.. (2023). 88. Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Garcia‐Manero, Guillermo, Lewis R. Silverman, Lucy Yan, & Wolfgang Dummer. (2023). PB2019: PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS. HemaSphere. 7(S3). e9155290–e9155290. 1 indexed citations

Yan, Lucy, Ziad Mallat, Suzana Margareth Lobo, Anuj Malik, & Wolfgang Dummer. (2022). 1141. Phase 3 Trial (in progress) of the SYK Inhibitor Fostamatinib in Patients Hospitalized with COVID-19: Protocol and Study Implementation Updates. Open Forum Infectious Diseases. 9(Supplement_2). 1 indexed citations

Sohn, Winnie, Anthony A. Portale, Isidro B. Salusky, et al.. (2018). An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. Pediatric Nephrology. 34(1). 145–154. 9 indexed citations

10.

Vu, Thuy, Peiming Ma, Jan de Hoon, et al.. (2017). Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharmaceutical Research. 34(9). 1784–1795. 72 indexed citations

11.

Hoon, Jan de, Anne Van Hecken, Corinne Vandermeulen, et al.. (2017). Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With Migraine. Clinical Pharmacology & Therapeutics. 103(5). 815–825. 73 indexed citations

12.

Palaparthy, Rameshraja, Christopher Banfield, Lucy Yan, et al.. (2015). Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 54(3). 217–227. 23 indexed citations

13.

Gordon, Michael S., Christopher J. Sweeney, David S. Mendelson, et al.. (2010). Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(2). 699–710. 133 indexed citations

14.

Coxon, Angela, Karen Rex, Jan Sun, et al.. (2008). Exploratory biomarkers in the HGF/SF:c-Met axis: preclinical and clinical results. Cancer Research. 68. 2804–2804. 2 indexed citations

15.

LoRusso, Patricia, Elisabeth I. Heath, Jesse McGreivy, et al.. (2008). Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Investigational New Drugs. 26(5). 455–462. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact